Market research kept out of Sunshine law

Market research kept out of Sunshine law
Market research kept out of Sunshine law

Market researchers should be able to breathe a little bit easier. The Physician Payment Sunshine Act, draft guidelines for which were recently issued after a delay of several months, maintains the exclusion for marketing research incentives, and all but one or two states have yielded to it.

Reacting to Sunshine's passage, over the past year-and-a-half, Maine, New York, Alaska, Connecticut, Colorado as well as the District of Columbia are among those that have either killed their reporting regulations for research, or shelved bills.

The only state where firms cannot pay a physician to participate in a pharma research study is Vermont, said Howard Fienberg, director of government affairs for the Marketing Research Association (MRA), one of the groups that have been lobbying for exclusions along with the Pharmaceutical Markeing Research Group (PMRG). Vermont's law is “a flat, specific [gift] ban which would not be preempted in the slightest by the [federal law].”

Research honoraria are exempt from federal physician-payment regulation, as long as the pharma or medical device manufacturer sponsoring the survey or focus group is not aware of the participants' identity.

West Virgina, Fienberg added, could still be on the radar but is not enforcing its law.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.